Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy (ALINET)

Federico II University

Status: Enrolling

Conditions: Hypercholesterolaemia

Treatments: Drug: Praluent (Alirocumab)

Study type: Observational

Funder types: Other

Identifiers

NCT07375225

Prot. 28/2024

Details and patient eligibility

About

Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

- Patients under alirocumab 300mg treatment.

Exclusion criteria

• Age < 18 years o > 80 years;
• Patients who refuse to participate and to sign informed consent.

Trial design

1,500 participants in 1 patient group

Subjects with hyperlipidaemia under Alirocumab 300 mg treatment.

Description:

Subjects with hyperlipidaemia

Treatment:

Drug: Praluent (Alirocumab)